Cargando…
Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023
Monoclonal antibodies (mAbs) are an important treatment option for COVID-19 caused by SARS-CoV-2, especially in immunosuppressed patients. However, this treatment option can become ineffective due to mutations in the SARS-CoV-2 genome, mainly in the receptor binding domain (RBD) of the spike (S) pro...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609123/ https://www.ncbi.nlm.nih.gov/pubmed/37894075 http://dx.doi.org/10.3390/microorganisms11102417 |
_version_ | 1785127939296198656 |
---|---|
author | Haars, Jonathan Palanisamy, Navaneethan Wallin, Frans Mölling, Paula Lindh, Johan Sundqvist, Martin Ellström, Patrik Kaden, René Lennerstrand, Johan |
author_facet | Haars, Jonathan Palanisamy, Navaneethan Wallin, Frans Mölling, Paula Lindh, Johan Sundqvist, Martin Ellström, Patrik Kaden, René Lennerstrand, Johan |
author_sort | Haars, Jonathan |
collection | PubMed |
description | Monoclonal antibodies (mAbs) are an important treatment option for COVID-19 caused by SARS-CoV-2, especially in immunosuppressed patients. However, this treatment option can become ineffective due to mutations in the SARS-CoV-2 genome, mainly in the receptor binding domain (RBD) of the spike (S) protein. In the present study, 7950 SARS-CoV-2 positive samples from the Uppsala and Örebro regions of central Sweden, collected between March 2022 and May 2023, were whole-genome sequenced using amplicon-based sequencing methods on Oxford Nanopore GridION, Illumina MiSeq, Illumina HiSeq, or MGI DNBSEQ-G400 instruments. Pango lineages were determined and all single nucleotide polymorphism (SNP) mutations that occurred in these samples were identified. We found that the dominant sublineages changed over time, and mutations conferring resistance to currently available mAbs became common. Notable ones are R346T and K444T mutations in the RBD that confer significant resistance against tixagevimab and cilgavimab mAbs. Further, mutations conferring a high-fold resistance to bebtelovimab, such as the K444T and V445P mutations, were also observed in the samples. This study highlights that resistance mutations have over time rendered currently available mAbs ineffective against SARS-CoV-2 in most patients. Therefore, there is a need for continued surveillance of resistance mutations and the development of new mAbs that target more conserved regions of the RBD. |
format | Online Article Text |
id | pubmed-10609123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106091232023-10-28 Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023 Haars, Jonathan Palanisamy, Navaneethan Wallin, Frans Mölling, Paula Lindh, Johan Sundqvist, Martin Ellström, Patrik Kaden, René Lennerstrand, Johan Microorganisms Article Monoclonal antibodies (mAbs) are an important treatment option for COVID-19 caused by SARS-CoV-2, especially in immunosuppressed patients. However, this treatment option can become ineffective due to mutations in the SARS-CoV-2 genome, mainly in the receptor binding domain (RBD) of the spike (S) protein. In the present study, 7950 SARS-CoV-2 positive samples from the Uppsala and Örebro regions of central Sweden, collected between March 2022 and May 2023, were whole-genome sequenced using amplicon-based sequencing methods on Oxford Nanopore GridION, Illumina MiSeq, Illumina HiSeq, or MGI DNBSEQ-G400 instruments. Pango lineages were determined and all single nucleotide polymorphism (SNP) mutations that occurred in these samples were identified. We found that the dominant sublineages changed over time, and mutations conferring resistance to currently available mAbs became common. Notable ones are R346T and K444T mutations in the RBD that confer significant resistance against tixagevimab and cilgavimab mAbs. Further, mutations conferring a high-fold resistance to bebtelovimab, such as the K444T and V445P mutations, were also observed in the samples. This study highlights that resistance mutations have over time rendered currently available mAbs ineffective against SARS-CoV-2 in most patients. Therefore, there is a need for continued surveillance of resistance mutations and the development of new mAbs that target more conserved regions of the RBD. MDPI 2023-09-27 /pmc/articles/PMC10609123/ /pubmed/37894075 http://dx.doi.org/10.3390/microorganisms11102417 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Haars, Jonathan Palanisamy, Navaneethan Wallin, Frans Mölling, Paula Lindh, Johan Sundqvist, Martin Ellström, Patrik Kaden, René Lennerstrand, Johan Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023 |
title | Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023 |
title_full | Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023 |
title_fullStr | Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023 |
title_full_unstemmed | Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023 |
title_short | Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023 |
title_sort | prevalence of sars-cov-2 omicron sublineages and spike protein mutations conferring resistance against monoclonal antibodies in a swedish cohort during 2022–2023 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609123/ https://www.ncbi.nlm.nih.gov/pubmed/37894075 http://dx.doi.org/10.3390/microorganisms11102417 |
work_keys_str_mv | AT haarsjonathan prevalenceofsarscov2omicronsublineagesandspikeproteinmutationsconferringresistanceagainstmonoclonalantibodiesinaswedishcohortduring20222023 AT palanisamynavaneethan prevalenceofsarscov2omicronsublineagesandspikeproteinmutationsconferringresistanceagainstmonoclonalantibodiesinaswedishcohortduring20222023 AT wallinfrans prevalenceofsarscov2omicronsublineagesandspikeproteinmutationsconferringresistanceagainstmonoclonalantibodiesinaswedishcohortduring20222023 AT mollingpaula prevalenceofsarscov2omicronsublineagesandspikeproteinmutationsconferringresistanceagainstmonoclonalantibodiesinaswedishcohortduring20222023 AT lindhjohan prevalenceofsarscov2omicronsublineagesandspikeproteinmutationsconferringresistanceagainstmonoclonalantibodiesinaswedishcohortduring20222023 AT sundqvistmartin prevalenceofsarscov2omicronsublineagesandspikeproteinmutationsconferringresistanceagainstmonoclonalantibodiesinaswedishcohortduring20222023 AT ellstrompatrik prevalenceofsarscov2omicronsublineagesandspikeproteinmutationsconferringresistanceagainstmonoclonalantibodiesinaswedishcohortduring20222023 AT kadenrene prevalenceofsarscov2omicronsublineagesandspikeproteinmutationsconferringresistanceagainstmonoclonalantibodiesinaswedishcohortduring20222023 AT lennerstrandjohan prevalenceofsarscov2omicronsublineagesandspikeproteinmutationsconferringresistanceagainstmonoclonalantibodiesinaswedishcohortduring20222023 |